References
- Desport E, Bridoux F, Sirac C, et al. AL Amyloidosis. Orphanet J Rare Dis. 2012;7(1):54.
- Zhang N, Cherepanov D, Romanus D, et al. Estimating the global epidemiology of amyloid light-chain amyloidosis with an incidence-to-prevalence model. (#SP-232) 17th international myeloma workshop. Boston. 2019 September 12;15:2019.
- Wechalekar AD, Gillmore JD, Bird J, et al. Guidelines on the management of AL amyloidosis. Br J Haematol. 2015;168(2):186–206.
- Palladini G, Milani P, Merlini G. Management of AL amyloidosis in 2020. Blood. 2020;136(23):2620–2627.
- Palladini G, Sachchithanantham S, Milani P, et al. A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. Blood. 2015;126(5):612–615.
- Manwani R, Cohen O, Sharpley F, et al. A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib. Blood. 2019;134(25):2271–2280.
- Kastritis E, Leleu X, Arnulf B, et al. Bortezomib, Melphalan, and Dexamethasone for light-chain amyloidosis. J Clin Oncol. 2020;38(28):3252–3260.
- Zhang KW, Stockerl-Goldstein KE, Lenihan DJ. Emerging therapeutics for the treatment of light chain and transthyretin amyloidosis. JACC Basic Transl Sci. 2019;4(3):438–448.
- Merlini G, Dispenzieri A, Sanchorawala V, et al. Systemic immunoglobulin light chain amyloidosis. Nat Rev Dis Primers. 2018;4(1):1–19.
- National Comprehensive Cancer Network (2020). NCCN clinical practice guidelines in oncology - systemic light chain amyloidosis. 1.2021, 1–26. Available online at: https://www.nccn.org/professionals/physician_gls/. Accessed 2020 Sept 23.
- Kastritis E, Palladini G, Minnema MC, et al. ANDROMEDA trial investigators. Daratumumab-based treatment for immunoglobulin light-chain amyloidosis. N Engl J Med. 2021 Jul 1;385(1):46–58. PMID: 34192431.
- Sullivan SD, Mauskopf JA, Augustovski F, et al. (2014) Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact analysis good practice II task force. Value Health 17 1: 5–14.
- https://www.cystat.gov.cy/el/default?OpenDocument cited Jul 2022
- Suzuki K, Wechalekar AD, Kim K, et al. Subcutaneous daratumumab (DARA SC) + bortezomib, cyclophosphamide, and dexamethasone (VCd) in Asian patients with newly diagnosed light-chain (AL) amyloidosis: subgroup analysis from the phase 3 ANDROMEDA study. Poster presented at: Virtual 62nd American Society of Hematology (ASH) Annual Meeting & Exposition; Dec 5-8, 2020.
- Quock TP, Yan T, Chang E, et al. Epidemiology of AL amyloidosis: a real-world study using US claims data. Blood Adv. 2018;2(10):1046–1053.
- Dispenzieri A, Lacy MQ, Kyle RA, et al. Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival. J Clin Oncol. 2001;19:3350–3356. [PubMed] [Google Scholar].
- Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation. 2005;112(13):2047–2060.
- https://www.gesy.org.cy/sites/Sites?d=Desktop&locale=el_GR&lookuphost=/el-gr/&lookuppage=hioactivitycatinpatientjune2020 cited Jul 2022
- https://www.gesy.org.cy/sites/Sites?d=Desktop&locale=el_GR&lookuphost=/el-gr/&lookuppage=hioactivitycatos29-07-2019 cited Jul 2022
- Alkhatib NS, Abraham I. The six Delta platform for outcome-based contracting for pharmaceuticals. J Med Econ. 2020;23(11):1209–1214.
- Premkumar VJ, Lentzsch S, Pan S, et al. Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis. Blood Cancer J. 2021;11:10.
- Cohen AD, Heather Landau EC. Scott, et al (2016) safety and efficacy of carfilzomib (CFZ) in previously-treated systemic light-chain (AL) amyloidosis. Blood. 2016;128:645.